Vectormune HVT LT (Canada)This page contains information on Vectormune HVT LT for veterinary use.
The information provided typically includes the following:
- Vectormune HVT LT Indications
- Warnings and cautions for Vectormune HVT LT
- Direction and dosage information for Vectormune HVT LT
Vectormune HVT LTThis treatment applies to the following species:
FOWL LARYNGOTRACHEITIS-MAREK’S DISEASE VACCINE
Serotype 3, Live Marek’s Disease Vector
Directions For Use
VECTORMUNE® HVT LT contains a genetically engineered Marek’s disease vaccine of serotype 3 (turkey herpesvirus or HVT) expressing a laryngotracheitis virus key protective antigen. This vaccine is recommended for use in chickens as an aid in the prevention of laryngotracheitis and Marek’s disease. This Marek’s disease vaccine containing serotype 3 is presented in a frozen cell associated form. The cells and virus particles are very fragile and require careful handling to prevent damage or loss of titer in order to achieve optimum efficacy. The vaccine is stored and shipped in frozen form in liquid nitrogen.
- Vaccine ampules: Store in liquid nitrogen
- Diluent: Store at room temperature between 68-77°F (20-25°C)
Vectormune HVT LT Indications
The vaccine is recommended for use in healthy 0-day-old chicks or in 18 to 19 day-old embryonated chicken eggs as an aid in the prevention of laryngotracheitis and Marek’s disease. Good management practices are recommended to reduce exposure to laryngotracheitis virus and Marek’s disease virus for at least two weeks following vaccination. Duration of immunity for the laryngotracheitis fraction is at least six weeks. Duration of immunity for the Marek’s disease fraction has not been established.
Preparation And Administration Of Vaccine
Carefully read the directions before use. The instructions must be completely followed. Match the vaccine dose size to the proper diluent size and route of administration as follows:
1. For subcutaneous injection of 0-day-old chicks
Mix 200 ml of diluent for each 1000 doses of vaccine
2. For in ovo vaccination of 18 to 19 day-old chicken embryos
Mix 100 ml of diluent for each 1000 doses of vaccine to administer 0.1 ml per chicken embryo or mix 50 ml for each 1000 doses of vaccine to administer 0.05 ml per chicken embryo.
1. Be familiar with all safety and precautionary measures for handling liquid nitrogen to prevent personal injury.
2. Wear gloves, a plastic face shield and protective goggles before removing vaccine ampules from the liquid nitrogen.
3. Check the container to confirm a sufficient amount of liquid nitrogen is present to keep the vaccine frozen. If thawed, do not use the vaccine. The containers (Dewars) must be checked regularly for liquid nitrogen level and must be refilled as needed.
4. After matching the dose size of the vaccine with the diluent size, quickly remove the exact number of ampules needed.
5. A maximum of 3 ampules should be thawed at one time. After inspecting the diluent and completing all preparations, the vaccine should be quickly removed from the Dewar and placed into a clean 80°F (26.5°C) thaw bath. This step can be repeated until the appropriate dosage has been reached. Gentle agitation during the thawing process promotes rapid, uniform thawing and evenly distributes the vaccine in the ampule.
6. Immediately after thawing, mix the vaccine with the diluent at room temperature (68-77°F or 20-25°C). Gently draw the vaccine from the ampule with an 18-gauge, 1.5 inch needle and slowly mix with the diluent. Rinse the ampule one time with the diluted vaccine.
7. Immediately use the vaccine and mix occasionally to ensure uniform suspension of cells.
1. For subcutaneous injection, sterilize the automatic syringe, needles and other accessory equipment by autoclaving or boiling prior to vaccination.
2. Use a short (3/8 inch or 1/2 inch) 20-gauge needle for vaccination. Subcutaneously inject 0.2 ml into the back of the neck of each chick.
IN OVO VACCINATION
1. The vaccine is administered in ovo to 18 to 19 day-old embryonated eggs. Read the egg injection system operator’s manual before initiating vaccination. Failure to follow instructions may result in personal injury, excessive embryonic mortality and low hatchability. Inoculate each embryo with one full dose (0.05 ml or 0.1 ml).
2. Sanitize the egg injection system before and after use following the procedures described in the operator’s manual.
This vaccine has been thoroughly tested for safety, purity and potency and is in compliance with all applicable USDA and Biomune Co. standards
Vectormune HVT LT Caution
1. Read the above directions carefully.
2. Do not vaccinate within 21 days before slaughter.
3. The vaccine contains gentamicin and amphotericin B as preservatives.
4. Burn containers and all unused contents.
5. Do not remove vaccine from liquid nitrogen until ready for use.
6. Do not refreeze the vaccine.
7. Do not use vaccine that has thawed in the liquid nitrogen container.
8. Do not overdose or over dilute the vaccine.
9. The effect of combining this vaccine with other products is not known and could impact vaccine efficacy.
10. Even though studies performed by the manufacturer indicate that the recombinant vaccine virus is non-pathogenic to turkeys, precautionary measures should be taken to reduce the potential for spread of the virus to turkey populations, and the product should not be administered to chickens with probable direct or indirect exposure to turkeys.
Patent Numbers US
Manufactured By: BIOMUNE CO., Lenexa, KS 66215, U.S.A.
Phone: (913) 894-0230
U.S. Vet Lic. No. 368
Distributed By: Ceva Animal Health, Guelph, Ontario N1K 1E8
Presentation: 1,000 doses, 2,000 doses, and 4,000 doses.
NAC No.: 12211030
6-1040 FOUNTAIN ST. N., CAMBRIDGE, ON, N3E 1A3
|Every effort has been made to ensure the accuracy of the Vectormune HVT LT information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-05-31